Skip to content

MAnagement of Systolic Blood Pressure During Thrombectomy by Endovascular Route for Acute Ischaemic STROKE

MAnagement of Systolic Blood Pressure During Thrombectomy by Endovascular Route for Acute Ischaemic STROKE: the MASTERSTROKE Trial

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05645861
Acronym
MASTERSTROKE
Enrollment
550
Registered
2022-12-12
Start date
2019-11-28
Completion date
2026-02-28
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure, Embolus Cerebral, Stroke

Brief summary

Stroke is the third most common cause of death in New Zealand and is one of the leading causes of long-term disability at all ages. A life-saving clot retrieval procedure can save lives and prevent disability of patients with ischaemic stroke who get to hospital in time. In New Zealand, 90% of clot retrieval procedures are performed under general anaesthesia. Many anaesthetic drugs can affect blood pressure (BP) and blood flow within the brain. Increasing BP during the procedure could provide additional benefits in this devastating disease. A large trial is needed to investigate BP management during clot retrieval.

Detailed description

Internationally stroke ranks second among all causes of disability and is adding to considerable worldwide healthcare burden. Over the last 5 years a new procedure to remove clots (Endovascular Thrombectomy - EVT) has been effective for the treatment of acute large strokes, with significant reductions in long term patient disability compared to standard treatment. However, there minimal guidance on blood pressure management during the procedure. The brain is especially vulnerable to low blood pressure during the acute stroke period due to low blood supply, impairment of how the brain regulates blood flow and further falls in blood flow to the brain. High blood pressure may be beneficial due to increased blood flow in areas at risk during this time. It could be harmful due to brain injury process, swelling, and bleeding into the brain. Conversely, relatively low blood pressure could be harmful. Current evidence is limited to large observational studies. This randomised controlled study will examine the safety and efficacy of two systolic blood pressures (SBP) management arms during general anaesthesia for EVT on outcomes in patients with acute ischaemic stroke.

Interventions

PROCEDUREBlood pressure management of Systolic Blood Pressure to maintain target range +/- 10 mmHg

Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.

Sponsors

The Australian and New Zealand College of Anaesthetists (ANZCA)
CollaboratorUNKNOWN
Neurological Foundation of New Zealand
CollaboratorUNKNOWN
The University of Queensland
CollaboratorOTHER
Auckland Medical Research Foundation
CollaboratorOTHER
Auckland Hospitals Research and Endowment Fund
CollaboratorUNKNOWN
Auckland City Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Participant, investigators and outcome assessors are blinded to randomization allocation using opaque envelopes.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed with anterior circulation stroke (ICA or proximal M1 or M2 segment of MCA) treated with ECR within 6 hrs of stroke onset and ECR patients presenting within 6-24 hours and favourable penumbra on perfusion scanning (see criteria 1-3). Additional criteria in the 6 to 24-hour window. 1. 'wake up' stroke; CT with no (or at most minimal) acute infarction or 2. patient 80 years or older (NIHSS of 10 and infarct volume less than 21 ml on DWI or CT perfusion-CBF) 3. patient less than 80 years (NIHSS of 10 and infarct volume less than 31 ml on DWI or CT perfusion-CBF NIHSS of 20 and infarct volume less than 51 ml on DWI or CT perfusion-CBF).

Exclusion criteria

* Rescue' procedures eg acute ischaemic stroke associated with major medical procedures such as coronary artery stenting and coronary artery bypass * pre-stroke mRS\>=3 * not having GA * terminal illness with expected survival \<1 year * pregnancy * cardiovascular conditions where BP targeting will be contra-indicated * unable to participate in 3-month follow up

Design outcomes

Primary

MeasureTime frameDescription
Day 90 Modified Rankin Score90 days Post ThrombectomyThe Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 (no symptoms at all) to 5 (severe disability). A separate category of 6 is usually added for patients who are deceased.

Secondary

MeasureTime frameDescription
Independent functionality90 days Post ThrombectomyIndependent functional outcome as determined by a modified Rankin Score of 0,1,or 2 at 90 Days. The Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 (no symptoms at all) to 5 (severe disability). A separate category of 6 is usually added for patients who are deceased.
Days Alive out of Hospital (DAOH)90 days Post ThrombectomyThe number of days a participant spends at home in the first 90 days post-stroke (home days/DAH90 confirmed by patient follow-up and clinical note review.
All cause mortality90 days Post ThrombectomyAll cause mortality confirmed by patient follow-up and clinical note review.
Intraprocedural complicationsFrom randomisation until 36 hours post treatmentProportion of patients with intra-procedural complications (target vessel dissection, intracerebral haemorrhage, groin haematoma) as documented in medical records.
Complicaiton of importance - symptomatic intracranial haemorrhageFrom randomisation until 36 hours post treatmentProportion of patients with symptomatic intracranial haemorrhage (within 36 hours of treatment) as documented in medical records.

Countries

Australia, New Zealand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026